GW Pharma scuttles UK listing to trade on US market

GW Pharmaceuticals, a high-flying biotech firm in the United Kingdom that is seeking U.S. regulatory approval for a CBD-based drug, has abandoned its U.K. stock market listing to instead trade exclusively in the United States.

The firm announced it would ditch its Aim market listing this December, according to Britain’s Telegraph newspaper.

A company executive said it no longer needed a dual listing because the majority of its shares are now traded on the Nasdaq and held by U.S. investors.

GW Pharma is developingĀ Epidiolex, a cannabis-based epilepsy drugĀ for children. If approved by the U.S. Food and

...

GW Pharma scuttles UK listing to trade on US market is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs